Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials by Anna R. Schreiber, Jodi A. Kagihara, Jennifer A. Weiss, Andrew Nicklawsky, Dexiang Gao, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond

Get full text

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Can... by Anastasia A. Ionkina, John J. Tentler, Jihye Kim, Anna Capasso, Todd M. Pitts, Karen A. Ryall, Rebekah R. Howison, Peter Kabos, Carol A. Sartorius, Aik Choon Tan, S. Gail Eckhardt, Jennifer R. Diamond

Get full text

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer by Todd M. Pitts, Dennis M. Simmons, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, John J. Tentler, Diana Cittelly, D. Ryan Ormond, Wells A. Messersmith, S. Gail Eckhardt, Jennifer R. Diamond

Get full text

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis by Stephen G. Smoots, Anna R. Schreiber, Marilyn M. Jackson, Stacey M. Bagby, Adrian T A. Dominguez, Evan D. Dus, Cameron A. Binns, Morgan MacBeth, Phaedra A. Whitty, Jennifer R. Diamond, Todd M. Pitts

Get full text

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors by Jarushka Naidoo, Maria L Ascierto, Matthew D Hellmann, Ding Wang, Susana Banerjee, Mayukh Das, Panagiotis Kourtesis, Jennifer R Diamond, Teresa Alonso-Gordoa, Sandip P Patel, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Benedito A Carneiro

Get full text

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer by John J. Tentler, Julie Lang, Anna Capasso, Deog Joong Kim, Ely Benaim, Young B. Lee, Andrew Eisen, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, Todd M. Pitts, Roberta Pelanda, S. Gail Eckhardt, Jennifer R. Diamond

Get full text

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer by S. Lindsey Davis, Sarah J. Hartman, Stacey M. Bagby, Marina Schlaepfer, Betelehem W. Yacob, Tonia Tse, Dennis M. Simmons, Jennifer R. Diamond, Christopher H. Lieu, Alexis D. Leal, Elaine B. Cadogan, Gareth D. Hughes, Stephen T. Durant, Wells A. Messersmith, Todd M. Pitts

Get full text

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis by Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortés

Get full text

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer by Jennifer R. Diamond, S. G. Eckhardt, Todd M. Pitts, Adrie van Bokhoven, Dara Aisner, Daniel L. Gustafson, Anna Capasso, Sharon Sams, Peter Kabos, Kathryn Zolman, Tiffany Colvin, Anthony D. Elias, Anna M. Storniolo, Bryan P. Schneider, Dexiang Gao, John J. Tentler, Virginia F. Borges, Kathy D. Miller

Get full text

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial by John Hilton, Mihaela Cristea, Sophie Postel-Vinay, Capucine Baldini, Mark Voskoboynik, William Edenfield, Geoffrey I. Shapiro, Michael L. Cheng, Jacqueline Vuky, Bradley Corr, Sharmila Das, Abraham Apfel, Ke Xu, Martin Kozicki, Keziban Ünsal-Kaçmaz, Amy Hammell, Guan Wang, Palanikumar Ravindran, Georgia Kollia, Oriana Esposito, Shodeinde Coker, Jennifer R. Diamond

Get full text

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors by Anna R. Schreiber, Jodi A. Kagihara, Bradley R. Corr, S. Lindsey Davis, Christopher Lieu, Sunnie S. Kim, Antonio Jimeno, D. Ross Camidge, Jud Williams, Amy M. Heim, Anne Martin, John A. DeMattei, Nisha Holay, Todd A. Triplett, S. Gail Eckhardt, Kevin Litwiler, James Winkler, Anthony D. Piscopio, Jennifer R. Diamond

Get full text

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer by Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer

Get full text